Multiple studies conducted on KRAS WT tumours identified targetable oncogene fusions such as ALK, BRAF, FGFR2, MET, NRG1, NTRK1, NTRK3, RAF1, ROS1, EGFR, ERBB4, FGFR3, and RET. This evidence concerns the gene KRAS and neoplasm.